Development of high-throughput screens for discovery of kinesin adenosine triphosphatase modulators

被引:28
作者
Funk, CJ [1 ]
Davis, AS [1 ]
Hopkins, JA [1 ]
Middleton, KM [1 ]
机构
[1] Cytoskeleton Inc, Denver, CO 80223 USA
关键词
kinesin; ATPase; monastrol; Eg5; AnBimC; MKLP1; kinesin heavy chain; KIF3C; chromokinesin KIF4A; CENP-E; MCAK; KIFC3; high-throughput screening;
D O I
10.1016/j.ab.2004.02.032
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Kinesins are a group of related molecular motor proteins that have great potential as targets for antimitotic drug development. We have developed two novel assays, one end-point and one kinetic, that are useful for the discovery and optimization of kinesin modulators. Both assays measure inorganic phosphate (Pi) generated by microtubule-activated kinesin adenosine triphosphatase activity. The assays were validated using the mitotic Eg5 kinesin-specific inhibitor, monastrol. A panel of nine kinesin motor domain proteins, representing 8 of the 14 classes of kinesins, was screened. The coefficient of variation for both assays was determined to be 4-14%, depending on the panel member. Using the Eg5 kinetic assay with monastrol the IC50 value was 12 muM, which agrees well with previously published results. Two other closely related mitotic kinesins (AnBimC and MKLP1) were found to have IC50 values in the millimolar range. The other panel members (kinesin heavy chain, chromokinesin KIF4A, KIF3C, CENP-E, MCAK, and KIFC3) were not significantly inhibited by millimolar levels of monastrol. It is anticipated that screening of the nine-member panel of kinesins in these assays will serve as a platform for the discovery and development of specific kinesin modulators. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:68 / 76
页数:9
相关论文
共 38 条
[1]  
Blangy A, 1998, CELL MOTIL CYTOSKEL, V40, P174, DOI 10.1002/(SICI)1097-0169(1998)40:2<174::AID-CM6>3.0.CO
[2]  
2-F
[3]  
BURKHART CA, 2001, BIOCHIM BIOPHYS ACTA, V1471, P1
[4]   The ATPases:: a new family for a family-based drug design approach [J].
Chène, P .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2003, 7 (03) :453-461
[5]   Protein kinases - the major drug targets of the twenty-first century? [J].
Cohen, P .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (04) :309-315
[6]   Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity [J].
Connelly, E ;
Markman, M ;
Kennedy, A ;
Webster, K ;
Kulp, B ;
Peterson, G ;
Belinson, J .
GYNECOLOGIC ONCOLOGY, 1996, 62 (02) :166-168
[7]   Interaction of the mitotic inhibitor monastrol with human kinesin Eg5 [J].
DeBonis, S ;
Simorre, JP ;
Crevel, I ;
Lebeau, L ;
Skoufias, DA ;
Blangy, A ;
Ebel, C ;
Gans, P ;
Cross, R ;
Hackney, DD ;
Wade, RH ;
Kozielski, F .
BIOCHEMISTRY, 2003, 42 (02) :338-349
[8]  
Duflos Alain, 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P55, DOI 10.2174/1568011023354452
[9]   Microtubule motors in spindle and chromosome motility [J].
Endow, SA .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1999, 262 (01) :12-18
[10]   A scintillation proximity assay for studying inhibitors of human tau protein kinase II/cdk5 using a 96-well format [J].
Evans, DB ;
Rank, KB ;
Sharma, SK .
JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS, 2002, 50 (2-3) :151-161